Literature DB >> 24846800

Detection rates and phenotypic spectrum of m.3243A>G in the MT-TL1 gene: a molecular diagnostic laboratory perspective.

J Chin1, R Marotta2, M Chiotis2, E H Allan2, S J Collins3.   

Abstract

The nucleotide change A to G at position m.3243 in the mitochondrial tRNA leucine (UUR) gene (MT-TL1) is the most common point mutation reported in association with the Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS) syndrome. Since the original description of this disorder, factors including random mitochondrial segregation and consequent variable tissue heteroplasmy are recognised to contribute to a much broader phenotypic spectrum associated with the MT-TL1 m.3243A>G mutation, often rendering the process of making a diagnosis complex. Reliance on clinicians' referral patterns means that for most molecular diagnostic laboratories, their positive identification rates for the common pathogenic mitochondrial DNA (mtDNA) mutations, including MT-TL1 m.3243A>G, is often relatively low compared to those reported in clinically targeted research studies. Herein, we report our results of consecutive prospective screening of 745 patients with a clinically suspected mitochondrial syndrome encompassing features associated with MT-TL1 m.3243A>G mutation.
Copyright © 2014 © Elsevier B.V. and Mitochondria Research Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  MELAS syndrome; Mitochondria; m.3243A>G point mutation; tRNA leucine

Mesh:

Substances:

Year:  2014        PMID: 24846800     DOI: 10.1016/j.mito.2014.05.005

Source DB:  PubMed          Journal:  Mitochondrion        ISSN: 1567-7249            Impact factor:   4.160


  9 in total

1.  Cystoid macular changes on optical coherence tomography in a patient with maternally inherited diabetes and deafness (MIDD)-associated macular dystrophy.

Authors:  Cynthia X Qian; Kari Branham; Naheed Khan; Steven K Lundy; John R Heckenlively; Thiran Jayasundera
Journal:  Ophthalmic Genet       Date:  2017-01-31       Impact factor: 1.803

Review 2.  MELAS syndrome and cardiomyopathy: linking mitochondrial function to heart failure pathogenesis.

Authors:  Ying-Han R Hsu; Haran Yogasundaram; Nirmal Parajuli; Lucas Valtuille; Consolato Sergi; Gavin Y Oudit
Journal:  Heart Fail Rev       Date:  2016-01       Impact factor: 4.214

3.  Sensitive quantification of m.3243A>G mutational proportion in non-retinal tissues and its relationship with visual symptoms.

Authors:  Nathaniel K Mullin; Kristin R Anfinson; Megan J Riker; Kelsey L Wieland; Nicole J Tatro; Todd E Scheetz; Robert F Mullins; Edwin M Stone; Budd A Tucker
Journal:  Hum Mol Genet       Date:  2022-03-03       Impact factor: 5.121

Review 4.  Use of Next-Generation Sequencing for Identifying Mitochondrial Disorders.

Authors:  Shafi Mahmud; Suvro Biswas; Shamima Afrose; Mohasana Akter Mita; Md Robiul Hasan; Mst Sharmin Sultana Shimu; Gobindo Kumar Paul; Sanghyun Chung; Md Abu Saleh; Sultan Alshehri; Momammed M Ghoneim; Maha Alruwaily; Bonglee Kim
Journal:  Curr Issues Mol Biol       Date:  2022-02-27       Impact factor: 2.976

Review 5.  The non-syndromic clinical spectrums of mtDNA 3243A>G mutation.

Authors:  Xiya Shen; Ailian Du
Journal:  Neurosciences (Riyadh)       Date:  2021-04       Impact factor: 0.906

6.  Next-generation sequencing technology in the diagnosis of mitochondrial disorders.

Authors:  Rizwan Ahmad; Mohammad Yusuf Hasan
Journal:  Int J Health Sci (Qassim)       Date:  2021 Jan-Feb

Review 7.  The molecular pathology of pathogenic mitochondrial tRNA variants.

Authors:  Uwe Richter; Robert McFarland; Robert W Taylor; Sarah J Pickett
Journal:  FEBS Lett       Date:  2021-02-12       Impact factor: 3.864

8.  Clinical and Molecular Characteristics in 100 Chinese Pediatric Patients with m.3243A>G Mutation in Mitochondrial DNA.

Authors:  Chang-Yu Xia; Yu Liu; Hui Liu; Yan-Chun Zhang; Yi-Nan Ma; Yu Qi
Journal:  Chin Med J (Engl)       Date:  2016-08-20       Impact factor: 2.628

9.  A MT-TL1 variant identified by whole exome sequencing in an individual with intellectual disability, epilepsy, and spastic tetraparesis.

Authors:  Alain Verloes; Lisenka E L M Vissers; Elke de Boer; Charlotte W Ockeloen; Leslie Matalonga; Rita Horvath; Richard J Rodenburg; Marieke J H Coenen; Mirian Janssen; Dylan Henssen; Christian Gilissen; Wouter Steyaert; Ida Paramonov; Aurélien Trimouille; Tjitske Kleefstra
Journal:  Eur J Hum Genet       Date:  2021-06-01       Impact factor: 4.246

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.